Frontline PARP inhibitor shrinks tumors in BRCA-positive breast patients

Frontline PARP inhibitor shrinks tumors in BRCA-positive breast patients

All 13 newly diagnosed breast cancer patients with BRCA mutations had their tumors shrink significantly when treated with a PARP inhibitor ahead of frontline presurgical chemotherapy in a pilot study at The University of... read more

Bifunctional drug could treat tumors resistant to current mTOR inhibitors

Bifunctional drug could treat tumors resistant to current mTOR inhibitors

The first known bifunctional inhibitor for the mechanistic target of rapamycin (mTOR) protein was developed to overcome current known mechanisms of tumor resistance to mTOR inhibitors.... read more